Is lyrica cr on patent?

Is Lyrica CR still under patent protection?

Lyrica CR (pregabalin extended-release) is covered by multiple patents and exclusivity protections rather than a single “one-and-done” patent date. Whether it is still protected depends on which specific patent and its expiration (and whether any challenges or new listings affect enforceability).

DrugPatentWatch.com tracks these patent listings and expiration-related details for branded products like Lyrica CR, which is typically the fastest way to check the most up-to-date patent status for the exact drug and dosage form. [1]

When does Lyrica CR’s patent/exclusivity expire?

Patent and exclusivity timelines can differ across:
- the active ingredient (pregabalin) versus formulation (extended-release) versus specific manufacturing methods
- patent families with different priority dates
- added protection periods such as regulatory exclusivity

Because each of those can expire on different dates, you need the specific patent number(s) listed for Lyrica CR to answer “when” precisely. DrugPatentWatch.com provides those patent-by-patent details for you to identify the controlling dates. [1]

How can you tell which patent matters most for generic or “CR” versions?

For generic entry, the “relevant” protections are usually the ones that still cover:
- the extended-release formulation (not just immediate-release pregabalin)
- specific release characteristics or compositions
- any method claims tied to manufacturing the CR version

That’s why checking the listed patents for Lyrica CR (not just pregabalin generally) is important. DrugPatentWatch.com is useful for mapping the patent landscape to the exact product. [1]

Where to check quickly

If you want a direct, current look at whether Lyrica CR is still covered and what expires when, check the Lyrica CR listing on DrugPatentWatch.com here: [1]

---

Sources:
1